Related Experiment Videos
The role of chemotherapy in diffuse aggressive lymphomas
V T DeVita1, S M Hubbard, R C Young
1Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
Seminars in Hematology
|April 1, 1988
Summary
Combination chemotherapy offers a cure for diffuse aggressive lymphomas. Research focuses on optimizing treatment programs, identifying risk factors, and using chemotherapy for early-stage disease, improving patient outcomes.
Area of Science:
- Oncology
- Hematology
- Clinical Therapeutics
Background:
- Diffuse aggressive lymphomas are treatable with combination chemotherapy, achieving long-term remission in 30-60% of advanced-stage patients.
- Therapeutic advancements since 1975 include novel chemotherapy regimens, risk factor identification, and early-stage disease treatment strategies.
Purpose of the Study:
- To review advancements in combination chemotherapy for diffuse aggressive lymphomas.
- To evaluate the impact of new therapeutic strategies, prognostic factors, and dose intensity on treatment outcomes.
- To assess the role of chemotherapy in early-stage disease management.
Main Methods:
- Review of combination chemotherapy programs for diffuse aggressive lymphomas.
- Analysis of studies identifying prognostic factors influencing durable complete remission.
- Evaluation of dose intensity and drug scheduling as treatment variables.
Main Results:
- Newer aggressive chemotherapy regimens show improved results compared to earlier studies.
- Dose intensity is a significant factor affecting patient outcomes.
- Early-stage disease uniformly benefits from combination chemotherapy, with or without radiotherapy.
Conclusions:
- Combination chemotherapy is a curative option for diffuse aggressive lymphomas.
- Optimizing chemotherapy regimens, understanding prognostic factors, and controlling dose intensity are crucial for improving curability.
- Chemotherapy is the primary treatment for early-stage disease, often combined with radiotherapy.